从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病的命名讨论

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)作为一个疾病名称一直以来都被认为是不够合适的。因此在2020年引入了新的术语代谢相关脂肪性肝病(MAFLD)来取代NAFLD。可是在3年后的德尔菲共识中,MAFLD又被新名称MASLD取代。孰优孰劣,众说纷纭。疾病名称对于医疗卫生行业是极为重要的,一个疾病的名称更改应慎之又慎。本文将对NAFLD及其更新命名的沿革加以梳理,总结有关命名的优势及不足,以供医学同道参考。

关键词: 非酒精性脂肪性肝病, 代谢相关脂肪性肝病, 代谢功能障碍相关脂肪性肝病, 命名

黄震霆, 徐小萍, 吴静. 从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病的命名讨论[J]. 肝脏, 2024, 29(8): 900-904.

/ 推荐

参考文献 52

[1]	范建高,李小英.NAFLD更名MAFLD、MASLD:背景、异同、对策[J].中华肝病杂志,2023,31(8):789-792.
[2]	Pierantonelli I, Svegliati-Baroni G. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH[J].Transplantation,2019,103(1):e1-e13.
[3]	张馨元,刘宇,王文玲等.非酒精性脂肪性肝病的诊断与评估[J].临床肝胆病杂志,2023,39(08):1780-1788.
[4]	彭琳瑞,王柳,杨晓玲等.非酒精性脂肪性肝病的管理[J].中国实用内科杂志,2023,43(12):1028-1030.
[5]	Amangurbanova M, Huang DQ, Loomba R. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD[J].Aliment Pharmacol Ther,2023,57(1):37-51.
[6]	Younossi ZM, Alqahtani SA, Alswat K, et al. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease[J].J Hepatol,2024,80(3):419-430.
[7]	Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What's in a name? Renaming 'NAFLD' to 'MAFLD'[J].Liver Int,2020,40(6):1254-1261.
[8]	Carol M, Pérez-Guasch M, Solà E, et al. Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life[J].PLoS One,2022,17(4):e0265153.
[9]	Lazarus JV, Kakalou C, Palayew A, et al. A Twitter discourse analysis of negative feelings and stigma related to NAFLD, NASH and obesity[J].Liver Int,2021,41(10):2295-2307.
[10]	赵冉,沙卫红.代谢相关脂肪性肝病的概念变更及其对临床实践的影响[J].实用医学杂志,2022,38(19):2390-2394.
[11]	薛芮,范建高.代谢相关脂肪性肝病新定义的国际专家共识简介[J].临床肝胆病杂志,2020,36(06):1224-1227.
[12]	Addison T. Observations on fatty degeneration of the liver[J]. Guys Hosp Rep, 1836, 1(476): 485.
[13]	Rokitansky CA. Skizze der Größen und Formabweichungen der Leber[J]. Bruchstück Med Jahrb des kaisl, königl österr Staates,1839,Bd 29 oder neueste Folge Bd 20 Wien: 557.
[14]	P. B. Diseases of the liver//Pepper W, Starr L. A System of Practical Medicine[M]. Philadelphia, PA: Lea Brothers & Co, 1885: 1050.
[15]	Connor CL. Fatty infiltration of the liver and the development of cirrhosis in diabetes and chronic alcoholism[J]. Am J Pathol,1938,14(3):347-364.
[16]	Lonardo A, Leoni S, Alswat KA, et al. History of Nonalcoholic Fatty Liver Disease[J].Int J Mol Sci,2020,21(16):5888.
[17]	Schaffner F, Thaler H. Nonalcoholic fatty liver disease[J].Prog Liver Dis,1986,8:283-298.
[18]	Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus[J].Nat Rev Gastroenterol Hepatol,2017,14(1):32-42.
[19]	Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease[J].Mol Metab,2020,42:101092.
[20]	Zhou J, Zhou F, Wang W, et al. Epidemiological Features of NAFLD From 1999 to 2018 in China[J].Hepatology,2020,71(5):1851-1864. doi:10.1002/hep.31150?
[21]	Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J].J Hepatol,2018,69(4):896-904.
[22]	Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed?[J]. Dig Dis,2005,23(1):72-82.
[23]	Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J].J Hepatol,2020,73(1):202-209.
[24]	Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol,2024, 29(1):101133.
[25]	Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J].Hepatology,2023, 78(6):1966-1986.
[26]	Chalasani N, Younossi Z, Lavine J E, et al. The diagnosis and management ofnonalcoholic fatty liver disease: Practice guidance from the American Association forthe Study of Liver Diseases[J].Hepatology,2018,67:328-57.
[27]	European Association for the Study of The L, European Association for the Study Of D, European Association for the Study Of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol,2016,64:1388-402.
[28]	Fouad Y, Gomaa A, Semida N, Ghany WA, Attia D. Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists[J].J Hepatol,2021,74(5):1254-1256.
[29]	Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease[J].Mol Metab,2021,50:101143.
[30]	Gutiérrez-Cuevas J, Lucano-Landeros S, López-Cifuentes D, Santos A, Armendariz-Borunda J. Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies[J].Cancers (Basel),2022,15(1):23.
[31]	Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world[J].Liver Int,2020,40(9):2082-2089.
[32]	Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD[J].Liver Int,2020,40(12):3018-3030.
[33]	陆伦根,尤红,谢渭芬等.肝纤维化诊断及治疗共识(2019年)[J].胃肠病学,2019,24(09):546-556.
[34]	Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD[J].Clin Gastroenterol Hepatol,2021,19(10):2172-2181.e6.
[35]	Kwon SY, Park J, Park SH, et al. MAFLD and NAFLD in the prediction of incident chronic kidney disease[J].Sci Rep,2023,13(1):1796.
[36]	Han E, Chun HS, Lee YH, et al. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study[J].J Gastroenterol Hepatol,2023,38(9):1598-1609.
[37]	Méndez-Sánchez N, Díaz-Orozco L, Córdova-Gallardo J. Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience[J].J Hepatol,2021,75(1):221-222.
[38]	Clayton M, Fabrellas N, Luo J, et al. From NAFLD to MAFLD: Nurse and allied health perspective[J].Liver Int,2021,41(4):683-691.
[39]	Nan Y, An J, Bao J, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease[J].J Hepatol,2021,75(2):454-461.
[40]	Shaltout I, Alkandari H, Fouad Y, Hamed AE. Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease[J].J Hepatol,2022,76(3):739-740.
[41]	Mendez-Sanchez N, Arrese M, Gadano A, et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease[J].Lancet Gastroenterol Hepatol,2021,6(1):65-72.
[42]	Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J].Hepatol Int,2020,14(6):889-919.
[43]	Shiha G, Alswat K, Al Khatry M, et al. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa[J]. Lancet Gastroenterol Hepatol,2021,6(1):57-64.
[44]	Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: Implications of a Premature Change in Terminology[J].Hepatology,2021, 73(3):1194-1198.
[45]	Duseja A, Taneja S. Changing Nomenclature from Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Fatty Liver Disease?- Not Only Premature But Also Confusing[J]. J Clin Exp Hepatol,2021,11(2):278-279.
[46]	Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2020,5(8):739-752.
[47]	Ng C, Chan K, Ou K, et al.IDDF2022-ABS-0132 Mafld and nafld in lean individuals. A prospective analysis of 12,505 lean individuals[J].Gut, 2022,71:A50..
[48]	Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical[J].J Hepatol,2024, 80(2):e76-e77.
[49]	De A, Bhagat N, Mehta M, Taneja S, Duseja A. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD[J].J Hepatol,2024,80(2):e61-e62.
[50]	Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and/or MAFLD[J].J Hepatol,2024,80(2):e62-e64.
[51]	Sanal MG. Is the change from NAFLD to MASLD driven by political correctness?[J].J Hepatol,2024,80(2):e74-e76.
[52]	Cusi K, Younossi Z, Roden M. From NAFLD to MASLD: Promise and pitfalls of a new definition ?[J].Hepatology,2024,79(2):E13-E15.

从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病的命名讨论

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 52

相关文章 15

编辑推荐

Metrics

本文评价

[1]	聂子杰, 沈潇垚, 胡晨, 陈光明. 非酒精性脂肪肝基因改造小鼠模型的研究进展[J]. 肝脏, 2024, 29(9): 1146-1149.
[2]	敬进华, 金星, 马旭, 张福礼, 赵雪静, 毕刚, 戴伯华, 刘瑛, 郭峰, 丁国宁. 基于肠-肝轴理论探讨NAFLD进展与肠道菌群的联系[J]. 肝脏, 2024, 29(9): 1150-1153.
[3]	丁荣蓉, 周新兰, 李秀芬, 黄丹, 林维佳, 陈良. 非肥胖型与肥胖型非酒精性脂肪肝血清脂质组学研究[J]. 肝脏, 2024, 29(8): 975-979.
[4]	葛宇, 王超群, 陈怡, 沈若宇, 董旭. 血清尿酸肌酐比值与非肥胖型代谢相关脂肪性肝病的相关性分析[J]. 肝脏, 2024, 29(8): 985-989.
[5]	陈光文, 蔡晓波, 陆伦根. 肝窦内皮细胞在非酒精性脂肪性肝炎中的作用[J]. 肝脏, 2024, 29(8): 998-1001.
[6]	杜冰莹, 宋舒瑛, 谢青. EASL-EASD-EASO 代谢相关脂肪性肝病管理临床实践指南简介[J]. 肝脏, 2024, 29(6): 621-625.
[7]	赵倩, 赵彩彦. 肝脏类器官与代谢相关脂肪性肝病[J]. 肝脏, 2024, 29(6): 628-630.
[8]	钱晓婧, 陈颖, 刘王振祖, 张家祺, 蒋元烨, 胡诚. 等热量低碳水化合物高蛋白饮食对非酒精性脂肪性肝病血清脂质的影响[J]. 肝脏, 2024, 29(6): 706-713.
[9]	曾静, 范建高. MASLD管理中无创检测替代肝活检添新证据:突破还是挑战？[J]. 肝脏, 2024, 29(5): 491-493.
[10]	龚丽, 胡凤. FibroScan及肝纤维化指数在NAFLD合并HBV感染患者肝纤维化评估中的应用[J]. 肝脏, 2024, 29(5): 512-515.
[11]	丁剑波, 李秀惠. 白细胞在非酒精性脂肪性肝病发生及进展中的作用[J]. 肝脏, 2024, 29(5): 599-602.
[12]	徐衍, 饶慧瑛. 从非酒精性脂肪性肝病到代谢相关脂肪性肝病的变迁[J]. 肝脏, 2024, 29(3): 255-257.
[13]	李雨蓉, 钟昌明, 王杰. 无创评分预测肝脂肪变性的优势与不足[J]. 肝脏, 2024, 29(3): 260-262.
[14]	刘云霄, 王转国, 徐强, 窦婧, 王晓波, 郭燕, 郭峰, 王晓忠. 肥胖和高尿酸血症对代谢相关脂肪性肝病脂肪变性和纤维化的影响[J]. 肝脏, 2024, 29(3): 303-307.
[15]	张怡, 崔蕾, 袁伯稳. 单纯性肥胖儿童发生代谢相关脂肪性肝病的危险因素分析[J]. 肝脏, 2024, 29(3): 308-312.